No significant financial relationships to disclose. This is an ASCO Meeting Abstract from the 2006 ASCO Annual Meeting. This abstract does not include a full text component.
Genomic risk stratification in breast cancer: A 10-year follow-up of a single-institution prospective cohort comparing Oncotype DX and MammaPrint. Real-world evidence on recurrence risk from ...
Drug resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, occurring via secondary mutations or bypass pathways, is frequent among non-small-cell lung cancer patients.
Clinically available KRAS inhibitors mainly target G12C, which is rare in PDAC and often acquires resistance. Oncogenic KRAS ...
EGFR-positive lung cancer is more common in non-smokers (particularly those with adenocarcinoma) and younger adults, as it often develops from a single genetic mutation rather than widespread DNA ...
Clinically available KRAS inhibitors mainly target G12C, which is rare in PDAC and often acquires resistance. Oncogenic KRAS inactivates RB1 via CDK4/6, while RB1 mutation is rare. Thus, CDK4/6 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results